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 STUDY PROTOCOL Open Access
Evaluation of lightweight fibreglass heel casts in
the management of ulcers of the heel in
diabetes: study protocol for a randomised
controlled trial
William Jeffcoate1*, Frances Game1,5, Patricia Price2, Ceri Phillips3 and Vivienne Turtle-Savage1,4
Abstract
Background: Ulcers of the heel in diabetes are the source of considerable suffering and cost. In the absence of
specific treatments, it has been suggested that removable, lightweight fibreglass heel casts may both promote
healing and reduce discomfort and pain. The aim of the study is to assess the effectiveness and cost-effectiveness
of fibreglass heel casts in the management of heel ulcers.
Methods/Design: This is an observer-blind, randomised controlled trial in which participants with diabetes and
heel ulcers (NPUAP/EPUAP grades 2, 3 or 4 and present for 2 or more weeks) are randomised to receive either usual
care plus lightweight fibreglass heel casts or usual care alone. Randomisation is undertaken by random number
sequence generation incorporated as part of the electronic case record form, and is stratified by both ulcer area
(less than versus equal to or greater than 1 cm2) and NPUAP/EPUAP grade. Participants are followed every two
weeks until healing or for 24 weeks. The primary outcome measure is healing at or before 24 weeks and maintained
for 4 weeks. Secondary outcomes include (i) ulcer-related outcomes: time to healing, change in ulcer area, minor and
major amputation, secondary infection and (ii) patient-related outcomes: local pain, mood and function (EQ-5D),
impact of the ulcer (Cardiff Wound Impact Schedule) and survival. Cost-effectiveness will be assessed using a
decision analytic model to estimate costs from the perspective of the UK NHS and personal social services and
health outcomes, including percent healing and Quality Adjusted Life Years gained.
Safety will be documented as adverse and serious adverse device effects.
Discussion: If it is possible to confirm significant clinical benefit and/or cost-effectiveness, this would have direct
implications for the management of this distressing and costly complication of diabetes
Trial registration number: ISRCTN62524796 Registered 29 March 2011
Keywords: Diabetic foot ulcer, Heel, Pressure sore, Ulcer healing, Diabetes complications, Neuropathy, Casting,
Off-loading, Amputation
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Background
Chronic ulceration of some part of the foot affects up to
15% of all people with diabetes at some stage, and is the
source of considerable cost and suffering [1]. The average
age at presentation is 67 years and many of those affected
are thus older aged, with significant co-morbidities and
often clinging to an independent existence. Only two thirds
of all ulcers heal without amputation within 12 months
and in these, the median time to healing is 78 days [2,3].
Forty percent of patients whose ulcers heal will develop a
recurrence within 12 months [4].
Ulcers of the heel present particular difficulties and it
has often been said traditionally that 'Heel ulcers don’t
heal'. Seven percent of heel ulcers result in amputation
of the limb in diabetes and 20% persist until death [5].
Despite this, a single centre review of a consecutive series
of 154 heel ulcers in 97 patients with diabetes managed in
UK revealed that the eventual incidence of healing of heel
ulcers without surgery was very similar to ulcers elsewhere
on the foot. The median time to healing was, however,
very much longer at 200 (24 to 1,225) days [5] - almost 3
times longer than ulcers elsewhere on the foot. A recent
multicentre survey in 14 centres in Europe reported that
the median time to healing of heel ulcers was very simi-
lar, at 237 days [6]. Heel ulcers in diabetes also differ
from ulcers elsewhere on the foot in that they are fre-
quently painful.
Many heel ulcers arise as a result of the pressure of
immobilisation, and pressure ulcers are very common in
acute hospitals. Repeated prevalence surveys in UK sug-
gest that 8 to 10% of all patients in acute hospital beds
develop a pressure ulcer, of which one third are on the
heel; half of all pressure ulcers are in people with diabetes.
The prevalence of pressure ulcers is higher in long-stay
hospitals and care homes (Pankhurst S, Clough A unpub-
lished data).
While the principles of care have been specified by the
National Institute for Clinical Excellence (NICE) and the
Royal College of Nursing (RCN) [7], and by the Inter-
national Working Group on the Diabetic Foot (Inter-
national Diabetes Federation) [8], there are no specific
interventions which have been shown to improve the out-
come. The use of a non-removable below-knee fibreglass
(total contact or variant) cast is known to hasten healing
in ulcers caused by abnormal pressure loading on other
parts of the foot [9], but it has been reported to be inef-
fective when the ulceration is on the heel [10].
In the absence of specific treatment of proven effect-
iveness in heel ulcers, a small number of specialists in
UK advocated the use of lightweight, removable fibreglass
heel casts, and produced uncontrolled observational evi-
dence that these devices result in both a reduced time to
healing and a prompt improvement in pain and discomfort.
Thus, healing was observed in 42 (84%) of a consecutive
series of 50 heel ulcers (in patients both with and without
diabetes, but all of whom had peripheral arterial disease),
with a median (range) time to healing of 6 (3 to 13) weeks
[11]. Although the apparent benefit seems greater than
would be expected for such a simple device, the findings of
this uncontrolled study are mirrored by the clinical impres-
sion of the applicants. The mechanism for any positive ef-
fect is not known but may relate to the reduction of
shearing and stretching forces applied to the surface of the
ulcer. Current strategies to reduce local forces in an area of
ulceration (or ulceration risk) are largely concentrated an
attempt to reduce vertical forces with minimal effect, if any,
on shear and on stretching.
Lightweight fibreglass heel casts take approximately
15 minutes to mould to the heel and can be easily fash-
ioned in a domiciliary setting. They are applied over the
primary wound dressing and held in place with an outer
dressing, being saved and re-used each time the dressing
is changed. They are replaced when stained, damaged or
lost, and can often be worn inside shoes. Health care pro-
fessionals can be trained in their use in approximately
30 minutes, and the material cost of each cast is approxi-
mately £7. Casts need to be replaced on average every
three weeks.
The purpose of the proposed study is to systematically
evaluate the effectiveness and cost implications of this sim-
ple and apparently beneficial intervention. The study was
funded by NHS National Institute for Health Research,
Health Technology Assessment Programme Grant 09/01/53.
Methods/Design
Study configuration
This will be an observer-blind, randomised controlled trial.
Randomisation will be stratified by ulcer grade (National
Pressure Ulcer Advisory Panel-European Pressure Ulcer
Advisory Panel (NPUAP-EPUAP) Grade 2, 3 or 4, see
below) and by ulcer area (greater than or equal to 25 mm2
and less than or equal to 1 cm2 or greater than 1 cm2),
using random permuted blocks of randomly varying size.
Randomisation will be undertaken by Nottingham Clinical
Trials Unit (CTU), using a web-based system.
NPUAP-EPUAP ulcer grading system
1. Non-blanchable erythema
2. Partial thickness
3. Full thickness skin loss
4. Full thickness tissue loss
5. Unstageable/Unclassified: full thickness skin or
tissue loss - depthunknown
Primary endpoint
The primary endpoint will be percentage of all ulcers
healed at or before 24 weeks (6 months). Healing will be
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defined as epithelialisation maintained for 4 weeks and
will be confirmed by an observer blind to the random-
isation group.
Secondary endpoints
(i) Ulcer-related outcomes
Time to healing, change in ulcer area (measured by both
acetate tracings and digital images analysed by using
appropriate software to define area), infection, major and
minor amputation, ulcer recurrence, secondary ulceration
on either limb and adverse device effects (ADEs).
(ii) Patient-related outcomes
Local pain (visual analogue scale; VAS), Euroqol-5D
(EQ-5D), Cardiff Wound Impact Schedule (CWIS), hos-
pital admission (relating primarily either to the heel ulcer
or not), hospital length of stay and death.
(iii) Cost-effectiveness
Cost-effectiveness will be assessed by developing a
decision-analytic model to estimate costs and health out-
comes, including percentage of healed ulcers and Quality
Adjusted Life Years (QALYs) gained. Costs will be com-
pared between the two groups using a bottom-up ap-
proach from the perspective of UK NHS and personal
social services. Data relating to the costs of training pro-
fessionals and the costs of heel casts and their application
will be collected by discussions with relevant clinical and
finance staff. Incremental cost-effectiveness and cost-
utility ratios will be generated for a series of time horizons
(including a lifetime perspective) that reflect management
of patients with diabetic ulcers of the heel. The findings
will be subjected to a series of one-way sensitivity analyses
to determine the degree to which variation in parameter
estimates affect the relative cost-effectiveness ratios. The
results will be used to model the likely effects over the par-
ticular time horizons and costs and effects will be dis-
counted at 3.5%. A probabilistic sensitivity analysis will be
conducted to investigate the joint uncertainty in param-
eter values and cost-effectiveness acceptability curves will
be generated. A budget impact analysis will be undertaken
for 1-year and 5-year periods and will compare the costs
to the health service of the use of heel casts in the man-
agement of ulcers of the heel in diabetes.
Safety endpoints
The study population is one which comprises older aged
people who will have a high prevalence of co-morbidities,
including renal, cardiac and cerebrovascular diseases.
Moreover, ulcers of the foot may themselves worsen and
lead to hospital admission because of infection or increas-
ing necrosis. Although no specific safety issues are fore-
seen with the use of the heel cast, significant events are
listed among the secondary outcome measures. Other un-
expected ADEs will be recorded and if considered serious
(SADE) will be reported to the sponsor in accordance with
the principles of Good Clinical Practice (GCP).
The trial will be stopped when the last recruited sub-
ject reaches the end of the trial. However, premature ter-
mination of the clinical trial may occur because of a
regulatory authority decision, change in opinion of the
Research Ethics Committee (REC), or safety problems at
the discretion of the Data Monitoring Committee (DMC)
or Sponsor. No formal interim analyses for efficacy are
planned by the Trial Management group (TMG). How-
ever, the DMC may need to assess efficacy in relation to
safety in order to advise the Trial Steering Committee
(TSC) appropriately. Stopping for safety will be based on
an informal assessment by the DMC of adverse events. To
aid interpretation of efficacy, Haybittle-Peto type boundar-
ies of ± 3 standard errors (P < 0.0027) will be adopted to
permit the DMC to break the blind with negligible effect
on the properties of the final analysis.
Recruitment at any centre may be stopped for reasons
including low recruitment and inadequate data recording.
Randomisation and blinding
Internet-based treatment assignment will be determined
by a computer-generated pseudo-random code using ran-
dom permuted blocks of randomly varying size, created
by the Nottingham CTU. Trial participants will be allo-
cated with equal probability to each treatment arm with
stratification by ulcer grade and ulcer size.
Participants will be randomised to be managed either
with usual care recommended by the RCN and NICE [7]
(see below) or with usual care plus a fibreglass heel cup.
For participants randomised to the intervention group, a
fibreglass heel cast will be made according to agreed proce-
dures by clinical research staff who have been trained to an
agreed level of competence. Participants or carers will be
provided with written and verbal instructions on its use.
Dressings may be changed as often as patients/carers feel
necessary but this will be at least twice weekly.
Components of usual care
 Formal assessment of ulcer and surrounding skin
 Provision of any necessary off-loading
 Debridement (i) sharp, (ii) other as appropriate
(but excluding the use of larvae)
 Appropriate dressing products
 Appropriate antibiotic therapy
 Nutrition and self care
 Optimal glycaemic control
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 Revascularisation if deemed clinically necessary
 Continued close observation
Study management
This trial will be conducted in accordance with independ-
ent ethics committee (IEC), relevant informed consent
regulations (Declaration of Helsinki), ISO-14155 Guide-
lines and the Data Protection Act 1998. In addition all
local regulatory requirements will be adhered to, in par-
ticular those which afford greater protection to the safety
of trial subjects. All investigators and research staff will be
fully trained in GCP, and the study will be conducted in
line with these principles. There will be an independent
DMC and a TSC and both will be constituted according
to Medical Research Council (MRC) guidelines. The study
has been approved by the Yorkshire & The Humber -
Leeds West National Research Ethics Committee (refer-
ence 10/H1307/124) under the UK National Integrated
Research Application Scheme. All participants gave writ-
ten informed consent.
Duration of the study and participant involvement
The start date was 1February 2011. Recruitment was
planned to continue until 31 August 2014 and the inter-
vention phase planned to end 28 February 2015. Recruit-
ment was terminated on 4 September 2014 by which
time 509 participants had been recruited.
Duration of participant involvement
If the ulcer remains unhealed, participants will have fort-
nightly assessments by the researcher and will remain in
the study for 24 weeks. If the ulcer heals, they will have
two more fortnightly assessments. If the ulcer remains
healed, they will then have only their 12-week and 24-
week assessments, unless these have already been done. If
the ulcer heals at 22 or 24 weeks, the participant will have
two further fortnightly assessments to confirm healing.
End of the study
The study will end when the final patient has completed
their final study visit.
Selection and withdrawal of participants
Recruitment
Patients will have diabetes associated with an ulcer
(NPUAP-EPUAP grades 2, 3 or 4 - see Table 1) on the
heel (that is affecting the skin below the malleoli but
overlying the calcaneum inferiorly, posteriorly, medially
or laterally) and which has been present for at least
2 weeks. Those affected will be identified by the health
care professionals usually caring for them in hospitals,
care homes or the community. The presence of peripheral
arterial disease, wound infection and other particular co-
morbidities (such as end-stage renal failure of immobilisa-
tion) will not be regarded as specific contraindications.
Screening log
A log will be kept at each centre which will list patients
screened but not included in the study. The data kept in
the log will include only the date of screening, patient
initials, age and reason for screen failure. The log will
not leave the clinical centre and the only data collected
from the centre will be the absolute numbers of patients
screened patients and the reasons for screen failure.
Inclusion criteria
 Type 1 or type 2 diabetes mellitus
 Age 18 years or over
 An ulcer of the heel (below the malleoli and
affecting the skin overlying the calcaneum) of
NPUAP-EPUAP Grade 2 to 4, which has been
present for 2 or more weeks and which has a
cross-sectional area ≥ 25 mm2. If there is more than
one heel ulcer, one - which will be the largest or that
judged most clinically significant - will be selected as
the index ulcer
 Subjects who are both able and willing to give
written informed consent
Exclusion criteria
 Frailty or disability which would mean that
participation in the study might have an adverse
effect on patient well-being and mood
 The need for any off-loading device to be
non-removable
 The likelihood of protocol violation because of
planned travel
 Those who withhold consent
 Active participation in another study of a wound
care product
 The use of topical negative pressure or application
of larvae to the index heel ulcer
Study procedure
Study device
The study device is a fibreglass heel cast, moulded to the
shape of the heel and split for easy removal and replace-
ment. The heel cast will be made according to a study
specific procedure and applied over the primary dressing
(and secondary dressing if appropriate) which will be
selected at the discretion of the patient’s usual carer.
The cast will be covered by a single layer of Softbanor
equivalent bandage and held in place by a retention
layer. Written instructions on device usage will be given
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Table 1 Fibreglass casts for heel ulcers in diabetes: trial profile
Screening
visit
Visit 1
Randomisation Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 Visit 13
Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 Week 22 Week 24
Check inclusion/
exclusion criteria
X X
Information about
study
X
Informed consent X
Patient
demographics
X
ABPI X
Neuropathy X
Wound size by
acetate tracing
X X X X X X X X X X X X X
Digital image after
debridement
X X X X X X X X X X X X X
Cast applied if
randomised to
cast group
X X X X X X X X X X X X
Medication log X X X X X X X X X X X X X
EQ-5D X X X
CWIS X X X
Pain VAS X X X X X X X X X X X X X X
Non-blinded
Assessment
X X X X X X X X X X X
Collect health
economic diary
X X X X X X X X X X X X X
Blinded
assessment
X X
Visit at
which ulcer
is judged
healed
2 weeks
after ulcer
first judged
healed
4 weeks
after ulcer
first judged
healed
Visit 7
Week 12
Visit 13
Week 24
Digital image after
debridement
X X X X X
Cast applied if
randomised to
cast group
X X X X X
Medication log X X X X X
EQ-5D X X
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Table 1 Fibreglass casts for heel ulcers in diabetes: trial profile (Continued)
CWIS X X
Pain VAS X X X X X
Non-blinded
assessment
X X X X X
Collect health
economic diary
X X X X X
Blinded assessment X X X X
If an ulcer is judged healed on or before Week 24, then healing should be confirmed by a blinded assessor as soon as possible, and within 4 days. If the ulcer breaks down within 4 weeks of first being judged healed,
the participant should continue in the study. If the ulcer remains healed, the participant needs to have 12 Week and 24 Week visits – unless these have already been done. ABPI, ankle brachial pressure index; CWIS,
Cardiff Wound Impact Schedule; EQ-5D, Euroqol-5D; VAS, visual analogue scale.
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to patients and care givers. Heel casts will be replaced
when worn or stained.
Study plan
Participants who give written informed consent will be
asked either to attend a research clinic, or will have the
necessary information and examination at another venue
which is convenient for them and their carer.
The following procedures will be performed at the ap-
propriate visit(s)
1. Prior to randomisation visit
The nature of the study will have been explained to
the patient/carer by their usual doctor/nurse/podiatrist
2. Randomisation visit 1 (week 0)
Check inclusion and exclusion criteria
Explain study to patient
Written informed consent/agreement
Documentation of demographics and baseline clinical
details, including:
 Assessment of neuropathy (loss of protective
sensation) using a 10 g monofilament applied to
three sites (hallux, first and fifth metatarsal heads)
on the sole of the index foot
 Assessment of peripheral arterial disease by
palpation of pedal pulses and ankle brachial pressure
index (ABPI)
 Ulcer grade by NPUAP/EPUAP
 Digital image of ulcer following any necessary
debridement
 Local pain assessment by VAS
 Patient well-being and function documented using
EQ-5D and Cardiff Wound Impact Schedule
(CWIS)
 Documentation of medication
 Tracing of ulcer area with acetate sheet for the
purposes of randomisation and stratification
Randomisation
3. Visits 2to 13 will be every 2 weeks (±4 days) to
24 weeks (visit 13)
During each visit a check will be made for healing. If
the ulcer is judged healed, it will be confirmed by
blinded a clinician within 4 days. It will then be reviewed
after two weeks (±4 days) weeks and 4 weeks (±4 days).
If the ulcer is thought to remain healed at 4 weeks, heal-
ing will be confirmed once more by a blinded clinician.
If the ulcer recurs during this period, the participant
should return to the intervention phase of the study. If
the ulcer does not recur, the participant should continue
to collect data for health economic analysis and should
be reviewed by the research staff at 12 and 24 weeks, as-
suming these dates have not already passed.
Other measures to be taken at different visits are
charted in Table 1. The wound will be cleaned, debrided
(when appropriate), traced and imaged at each visit be-
fore being redressed. Patient well-being and function will
be documented by completion of EQ-5D and CWIS
(weeks 12 (±1) and 24 (±2) only.
For participants randomised to the intervention group,
a fibreglass heel cast will be replaced as necessary by
trained personnel and the patient/carer will be given
written and verbal instructions on its use.
Protocol violations
The following will be regarded as a protocol violation:
 Failure to use the study intervention (fibreglass heel
cast) as recommended for more than 7 consecutive
days, or for more than a cumulative total of 14 days
during the course of the 24 week study. Those who
violate the protocol in this way alone will not be
withdrawn but will continue with fortnightly visits
The following will be regarded as a protocol violation
necessitating withdrawal from the study:
 Omission of more than one consecutive scheduled
fortnightly assessment by the researcher, or omission
of a total of 3 or more of these visits during the
24 week study, or until healing is confirmed
Withdrawals
A patient can be withdrawn from the study if:
 Consent/agreement is withdrawn
 The participant loses capacity
 It is found that they were recruited in error
 They have omitted more than one consecutive
scheduled fortnightly assessment by the researcher, or
omitted a total of three or more of these visits during
the 24 week study, or before healing is confirmed
 The participant is lost to follow-up
Assessment of safety
Adverse device effect (ADE)
This refers to any untoward and unintended response to
a medical device, including any effect resulting from in-
sufficiencies or inadequacies in the instructions for use
or the deployment of the device and any effect that is a
result of a user error. ADEs will be recorded as they are
reported whether spontaneously volunteered or in
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response to questioning about well-being at trial visits.
All ADEs will be documented in the subject’s medical
records and CRF and will be followed until resolution,
or for at least 30 days after discontinuation of the use of
the device, whichever comes first. The investigator will
assess causal relationship of the ADE to the investiga-
tional device according to the following classification:
 None: no relationship with investigational device.
Other factor(s) certainly or probably causative
 Possible: reasonable possibility that the event was
caused by the device, even though other possible
causative factor(s) may exist
 Probable: the event was certainly or probably caused
by the device, even though other possible causative
factor(s) may exist
The following definitions for rating severity of ADEs
may be used:
 Mild: signs or symptoms which are easily tolerated
and are transient and only mildly irritating. There is
no loss of time from normal activities and symptoms
do not require medication or a medical evaluation
 Moderate: discomfort sufficient to cause interference
with usual activities or require therapeutic
intervention; for example, concomitant medication
 Severe: incapacity with inability to do work or
undertake usual activities
Foreseeable ADEs
Foreseeable ADEs are those related to worsening of the
clinical state of the ulcer and will be reported as second-
ary outcomes. These include
Ulcer-related outcomes
Increase in ulcer area
Infection
Major and minor amputation
Ulcer recurrence
Secondary ulceration on either limb
Patient-related outcomes
Increase in pain
Worsening mood or function
Hospital admission (relating primarily to the heel ulcer)
Death from pre-existing medical conditions
SADEs
An ADE that has resulted in any of the consequences
characteristic of the serious criteria or that might have
led to any of these consequences if suitable action had
not been taken or if circumstances had been less oppor-
tune. These serious criteria are:
 Death
 Life threatening illness or injury
 Hospitalisation or prolongation of hospitalisation
 Permanent impairment of body structure or body
function
 Medical or surgical intervention required to prevent
any of the above
An unexpected SADE refers to any SADE, the specificity or
severity of which is not consistent with the current protocol.
SADE Reporting
All SADEss must be reported immediately to the Sponsor
and will be documented in the subject’s medical records
and CRF. All SADEs must be followed until resolution, or
for at least 30 days after discontinuation of device use,
whichever comes first.
Statistical analysis
Appropriate descriptive statistics will be presented for
each variable. Two-sided statistical test will be performed
and presented with exact P-values, with interval estimates
constructed using 95% as the level of confidence.
Descriptive statistics, analytical methods and sample
size considerations will be included. The study team to-
gether with the investigators will make the decisions re-
garding individual values belonging to a patient to be
excluded from the analysis; for example, out of range
values/values that cannot be objectively verified. The in-
vestigators will make the final decision regarding coding
on the reason(s) for withdrawal. The safety population
(SP) will comprise all randomised patients for the study
The intention-to-treat (ITT) population is defined as all
subjects who were randomised. Given the study is based
on a population with an expected high morbidity, the attri-
tion rate will be monitored closely. If the missing primary
outcome data fall within the 20 to 25% level, then ITT will
be completed without imputation in the first instance and
repeated with multiple imputation as a sensitivity analysis.
ITT is equal to SP in this study. Once a participant has a
healed wound, which is confirmed as ‘healed’, they will no
longer participate in the intervention phase of the study, as
they will have achieved the primary outcome. Such partici-
pants will be deemed to have completed their participation
in the efficacy part of the study and their data will be in-
cluded in the numbers ‘healed’ by 24 weeks.
Per protocol (PP) population is defined as a subset of
ITT population that has completed the treatment period
of maximum 24 weeks according to the protocol. The
following will be regarded as a protocol violation neces-
sitating exclusion from the PP analysis:
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 Failure to use the study intervention (fibreglass heel
cast) as recommended for more than 7 consecutive
days, or for more than a cumulative total of 14 days
during the course of the 24-week study
 Omission of more than one consecutive scheduled
fortnightly assessment by the researcher, or omission
of a total of 3 or more of these visits during the
24-week study
Statistical analyses of relevant safety and all efficacy vari-
ables will be performed on the ITT population. Addition-
ally, statistical analyses of efficacy variables concerning
ulcer measurements will be performed on the PP popula-
tion. If ITT and PP analyses of efficacy produce similar re-
sults, only the ITT analysis will be presented in the report,
and the PP analysis will briefly be summarised.
Statistical methods
All assumed continuously distributed variables will be in-
vestigated with regards to distribution. Transformation to
unconstrained scales for ulcer area and VAS for pain will
be considered. All continuously distributed variables will be
summarised by treatment at measured time points with n
= number of subjects, mean, 95% confidence interval (CI)
of mean, median, standard deviation (SD), minimum, and
maximum. Change from the baseline to the end will also
be summarised by treatment with n = number of subjects,
mean, median, SD, 95% CI of mean, minimum and max-
imum. All categorical (discrete including ordinal) variables
will be presented in contingency tables showing counts and
percentages for each treatment group at all time points.
Demographic and other baseline variables
All demographic and diagnostic ulcer assessments at base-
line will be presented descriptively with counts and rates.
In addition, age will be given descriptively with n, mean,
median, SD, minimum-maximum. These data will be pre-
sented by trial arm at baseline.
Primary outcome
Healing will be defined as epithelialisation maintained
for 4 weeks and will be confirmed by an observer blind
to randomisation group. Outcomes for all patients ran-
domised will be presented using a CONSORT flow
diagram.
Classification of outcome will include the following
rule set:
1. Amputation of the target limb is a ‘failed’ outcome
and classified as ‘not-healed’
2. For those who achieve healing during the
intervention phase (and are confirmed as healed)
but have an active ulcer at the 24-week assessment
will be counted as ‘healed’ but the recurrence/new
ulcer will be noted as a secondary outcome
3. For those who achieve healing during the
intervention phase (and are confirmed as healed)
but do not attend for the 24-week assessment will be
counted as ‘healed’
4. If the missing primary outcome data fall within the
20 to 25% level, then ITT will be completed without
imputation in the first instance and repeated with
multiple imputation as a sensitivity analysis
The primary endpoint will be percentage of all ulcers
healed at or before 24 weeks (6 months). Based on the
binary nature of the outcome, the unadjusted analysis of
the effect of treatment on the primary outcome will be
assessed using Logistic Regression. Results will be reported
as an odds ratios (OR), 95% CI and exact P-values.
A covariate adjusted analysis of the effect of treatment
on the primary outcome will be undertaken. All prog-
nostic variables and stratification variables at randomisa-
tion (ulcer area and NPUAP grade) will be eligible for
inclusion in the covariate adjusted model. Prognostic
variables shown to be strongly associated with outcome,
even if not shown to be imbalanced between treatment
groups, will be screened for inclusion in the covariate
adjusted model as they may remove bias from the esti-
mate of treatment effect.
Univariate logistic regression will be conducted to
evaluate the relationship between each prognostic vari-
able identified and the study primary outcome. Prog-
nostic variables (and those with a strong imbalance at
baseline) with a Likelihood Ratio Test (LRT) P-value
less than or equal to 0.15 will qualify for evaluation in
the maximum covariate adjusted model. Inferences will
not be drawn from the interpretation of this univariate
P-value, but will simply be used to describe the strength
of association between the prognostic variable and the
primary outcome.
All identified variables will be included in a maximum
covariate adjusted logistical regression model. The treat-
ment group term will be forced to stay in the maximum
model; the model outcome will be the primary outcome.
Using a backwards-stepwise elimination from the max-
imum model, the final covariate adjusted model will
contain all prognostics and unbalanced variables known
to have a meaningful bias on the estimate of the treat-
ment effect. The LRT P-value for the estimate of treat-
ment effect from this model will be reported, together
will the covariate adjusted OR for treatment effect, and
the appropriate 95% CI.
Secondary outcomes
Testing of the secondary outcome variables is exploratory
and the results should mainly be used for exploratory
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purposes. On this basis, no adjustments for multiple test-
ing will be performed.
The time to complete healing of the reference ulcer
between the two randomized groups is an important
secondary outcome and will be compared using survival
analysis. Kaplan-Meier survival curves will be produced
for the 2 groups and the median time to healing with
95% CI presented. Treatment effect will be explored using
a Cox proportional hazards model including stratification
factors (ulcer size and grade) initially. Participants’ heel ul-
cers that are not healed will be treated as censored and
their date of trial exit, or date of last available assessment,
or 168-day/trial cessation, as appropriate, will be used to
calculate their duration in the trial. Hazard ratio with 95%
CI will be given.
Final ulcer area will be analysed by treatment group
for those who remain unhealed at the end of the study,
using linear regression. As this exploratory analysis will
include a subset of the participants, the analysis will be
adjusting for baseline area, and any other variables that
are found to be imbalanced at baseline (ANCOVA: on
both an ITT and PP basis).
Ulcer related pain (measured on a VAS), will be ana-
lysed using linear regression and adjusting for baseline
pain score, ulcer area, duration of ulcer, and ulcer type
on both an ITT and PP basis.
Scores on standardised scales (EQ-5D) will be calcu-
lated in line with the guidelines provided by the original
authors. The three domain scores will be calculated on
the CWIS for each participant, in line with the standard
instructions for use: descriptive statistics will be used to
summarise these at each assessment. The standardised
areas under the curve (area under the curve for each par-
ticipant adjusted for the duration of available data) will be
reported for both groups and compared using a Wilcoxon
rank sum test.
Secondary variables: Descriptive
All other variables that will not be modelled formally
will be considered descriptively. These are:
(i) Concomitant medications
All concomitant medications will be listed descrip-
tively by study treatment.
(ii) Usual wound assessment and care requirements
Routine data related to the formal assessment of the
wound and surrounding skin will be presented descrip-
tively with counts and rates; provision of off-loading
will be presented as categorical data with changes to
device requirements recorded throughout the interven-
tion period noted.
Secondary variables: Safety
ADEs and withdrawals comprise safety data and will
be presented in line with standard reporting requirements.
SADEs will also be considered and presented by group.
Secondary outcome measures (incidence of foot infection,
major amputation, minor amputation, revascularisation
and falls leading to hospital admission) will be reported.
Using a negative binomial model and adjusting for the
same covariates as the primary analyses, the numbers of
adverse events in each participant between treatment
groups will be compared.
Missing data
Due to the design of the electronic CRF, within which a
missing field is not permitted, the amount of missing data
within an assessment visit should be kept to a minimum.
However, missing data could still occur due to failure to
attend for an assessment visit. Missing primary outcome
data will be investigated through multiple imputation as a
secondary sensitivity analysis of the primary outcome,
should the missing data fall within the 20to 25% range.
Determination of sample size
The expected prevalence of healed ulcer in the control
group and the treatment group is 40% and 55%, respect-
ively, at 24 weeks. With α = 0.05 and β = 1-power (power
80%) and an estimated rate of dropouts of 30% a total of
531 patients of both genders will be included (to achieve
186 in each group completing the intervention phase).
With 25% attrition, the number required is 496 (to achieve
186 in each group). The study will aim to recruit 500 pa-
tients and closely monitor the number of cases where the
primary outcome data are missing. All secondary analyses
will be interpreted with caution as the sample size calcula-
tion is based on the primary outcomes only. Internet-based
treatment assignment will be determined by a computer-
generated pseudo-random code using random permuted
blocks of randomly varying size, created by the Notting-
ham CTU. Trial participants will be allocated with equal
probability to each treatment arm with stratification by
ulcer grade and ulcer size.
Discussion
Ulcers of the heel constitute a major source of morbidity
and cost, and there has hitherto been no specific therapy
described. Recently, however, the use of lightweight
fibreglass heel casts has been described and has been re-
ported to improve both the incidence and speed of heal-
ing. The purpose of this trial is to document the efficacy
of this intervention, as well as its cost, when compared
to the use of defined criteria of best usual care.
The trial is randomised and while it is not possible to
blind either the participant or their carer to the allocated
arm of the study, the primary outcome measure (clinical
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healing) will be confirmed by a blinded observer. All
non-clinical measures (including digital images of ulcer,
measures of pain and discomfort) will be undertaken by
blinded observers.
The study population is designed to be as inclusive as
possible, with the aim of maximising the external validity
of any findings. Thus, the intention is that as large a per-
centage as possible of people with diabetes complicated
by ulceration of the heel could be included - including
those with active infection, as well as those with all but
the most severe peripheral arterial disease. This popula-
tion is, however, one with multiple co-morbidities, a
high expected incidence of unrelated illness and hospital
admission and a poor overall life-expectancy. It is for this
reason that a decision has been made to restrict safety
measures to device effects. It is also for this reason that
the sample size calculation allows for up to 30% attrition,
and this is based on previous experience gained in con-
ducting trials in this area.
While the primary outcome measure is that of healing,
the trial includes a number of secondary outcome mea-
sures. Principal among these are rate of change in ulcer
area - as an indication of the likelihood of eventual heal-
ing, and the experience of local pain and discomfort.
While most foot ulcers in diabetes are typically painless,
those on the heel are often the source of pain or other
discomfort and experience reported by those who have
used such casts in clinical practice is that reduction in
local discomfort is often observed.
Trial status
Recruitment started on 20 April 2011 and ceased on 4
September 2014 by which time 509 participants had been
randomised. A total of 35 centres were involved through-
out the UK, but recruitment was discontinued at 8 be-
cause of poor recruitment and/or poor documentation.
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